336 related articles for article (PubMed ID: 10093890)
1. [Anti-integrins--new platelet function inhibitors for therapy and prevention of acute coronary syndrome].
Schrör K
Wien Klin Wochenschr; 1999 Feb; 111(3):90-7. PubMed ID: 10093890
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
3. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Ciccone A; Motto C; Abraha I; Cozzolino F; Santilli I
Cochrane Database Syst Rev; 2014 Mar; (3):CD005208. PubMed ID: 24609741
[TBL] [Abstract][Full Text] [Related]
5. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
Starnes HB; Patel AA; Stouffer GA
Drugs; 2011 Oct; 71(15):2009-30. PubMed ID: 21985168
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Chong PH
Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
[TBL] [Abstract][Full Text] [Related]
7. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
8. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
10. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
Kereiakes DJ; Runyon JP; Kleiman NS; Higby NA; Anderson LC; Hantsbarger G; McDonald S; Anders RJ
Circulation; 1996 Sep; 94(5):906-10. PubMed ID: 8790024
[TBL] [Abstract][Full Text] [Related]
11. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacology of GP IIb/IIIa antagonists.
Schrör K; Weber AA
J Thromb Thrombolysis; 2003 Apr; 15(2):71-80. PubMed ID: 14618072
[TBL] [Abstract][Full Text] [Related]
14. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
15. Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.
De Vita M; Coluccia V; Burzotta F; Romagnoli E; Trani C
Curr Vasc Pharmacol; 2012 Jul; 10(4):448-53. PubMed ID: 22339256
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
Lapchak PA; Araujo DM
Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935
[TBL] [Abstract][Full Text] [Related]
17. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
[TBL] [Abstract][Full Text] [Related]
20. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
